A key implication of these results is that individuals carrying the HLA-DQA1*01:02 allele may preferentially present particular peanut-allergenic peptides for immune recognition, so although those individuals are at increased risk for allergy, they may also be at increased likelihood of therapeutic benefit from oral exposure. The gene discussed is HLA-DQA1; the disease is allergic disease.